Top Markets
Coin of the day
Hunan Er-Kang Pharmaceutical Co., Ltd Hunan Er-Kang Pharmaceutical Co., Ltd

Hunan Er-Kang Pharmaceutical Co., Ltd

300267
Rank in Stocks #9472
Hunan Er-Kang Pharmaceutical Co., Ltd is a pharmaceutical company that... Hunan Er-Kang Pharmaceutical Co., Ltd is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), completed drug formulations, and pharmaceutical excipients, serving both the Chinese domestic market and international clients. Its API portfolio features substances such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's principal finished medications include sulbenicillin sodium for injection and compound liquorice tablets. For conventional pharmaceutical excipients, it provides items like pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose. Furthermore, its advanced pharmaceutical excipient offerings encompass hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate along with its related product series. The firm was established in 2003 and is headquartered in Liuyang, China.
Share Price
$0.48835979
Last synced: 2026-08-28
Market Cap
$1.01B
Change (1 day)
-1.46%
Change (1 year)
-9.78%
Country
CN
Trade Hunan Er-Kang Pharmaceutical Co., Ltd (300267)

Category

Revenue for Hunan Er-Kang Pharmaceutical Co., Ltd (300267)
Revenue in Aug 2026 TTM: 0
According to Hunan Er-Kang Pharmaceutical Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hunan Er-Kang Pharmaceutical Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors